Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Serum albumin-mediated strategy for the effective targeting of SARS-CoV-2

Pushpendra Mani Mishra, Vladimir N. Uversky, Chayan K. Nandi

ARTICLE INFO

Keywords:
COVID-19
SARS CoV-2
Antiviral drug
Treatment strategy

ABSTRACT

Novel coronavirus (nCoV-19), also known as SARS CoV-2, is a pathogen causing an emerging infection that rapidly increases in incidence and geographic range, is associated with the ever-increasing morbidity and mortality rates, and shows severe economic impact worldwide. The WHO declares the nCoV-19 infection disease (COVID-19) a Public Health Emergency of International Concern on 30 January 2020 and subsequently, on March 11, 2020, declared it a Global Pandemic. Although some people infected with SARS CoV-2 have no symptoms, the spectrum of symptomatic infection ranges from mild to critical, with most COVID-19 infections being not severe. The common mild symptoms include body aches, dry cough, fatigue, low-grade fever, nasal congestion, and sore throat. More severe COVID-19 symptoms are typical of pneumonia, and upon progression, the patient’s condition can worsen with severe respiratory and cardiac problems. Currently, there is no drug or vaccine for curing patients. It has been observed that people with challenged immunity are highly prone to SARS CoV-2 infection and least likely to recover. Also, older adults and people of any age with serious underlying medical conditions might be at higher risk for severe forms of COVID-19. We are suggesting here a strategy for the COVID-19 treatment that could be effective in curing the patients in the current scenario when no efficient medicine or Vaccine is currently available, and Clinicians solely depend upon the performing trials with drugs with known antiviral activities. Our proposed strategy is based on the compilation of published scientific research and concepts. The different published research indicates the success of a similar strategy in different physiological conditions, and such a strategy is widely studied at the cellular level and in animal models.

Important information on finding a strategy for the COVID-19 cure

nCoV-19 or SARS CoV-2 first emerges in the Wuhan city of Hubei province of China in December 2019, and since then, this virus is rapidly spreading to the different parts of the world and causing the fatalities at a devastating rate particularly in the Italy, Spain, and United States [1,2]. The virus is given name Coronavirus due to the similarity of its spike protein to the crown (Latin corona) [3]. SARS CoV-2 virus belongs to group IV Coronavirus and is the member of the order Nidovirales, Family Coronaviridae, Subfamily Coronavirusae, and Genus Betacoronavirus [4]. The virus genome is a ~30 kb positive-sense single-stranded RNA that encodes structural, non-structural and accessory proteins. The virion is enveloped and spherical with a diameter of 60–140 nm and with the spike length of 9–12 nm. The phylogenetic study suggested a closer relation of this virus to bat-SL-CoVZXC21 and bat-CoVZC45 than to human SARS [5]. The early cases reported infection in people after attending the seafood and animal market, thereby suggesting the animal to human transmission of the virus. The later cases indicated the sustained human to human transmission of SARS CoV-2 [6,7]. Human to human transmission occurs through respiratory droplets and fomites. The primary site of infection is in epithelial cells of respiratory or enteric tracts while secondary sites are kidney and heart though in question [8]. Currently, there is no cure for the COVID-19, and clinicians are solely depending upon the drugs that could provide symptomatic relief. The clinical trials are performed using drugs that have been known to treat other viral infections/related diseases.

Our purpose in writing this hypothesis article is to shed some light on the well-known facts and highlight the strategy that can be used for COVID-19 treatment. The drugs or therapeutic materials are likely to be
effective in the COVID-19 treatment if they either block the entry of the viral particles to cells or block the intracellular viral components [9]. The latter property plays one of the important roles in halting the propagation of viruses from infected cells while blocking the virus particles at the extracellular site inhibits the cell infection. Many factors define the effectiveness of the drug molecules, including their sustainability in the environment and cell penetration capacity.

To efficiently treat the SARS-CoV-2 infection, we are proposing the strategy of simultaneous targeting the viral particle extracellularly and intracellularly. To ensure the effective internalization of the potential drugs with demonstrated activity against the viral protease, polymerase, and RNA, serum albumin could be used as an excellent delivery vehicle. Serum albumin is a multifunctional protein known to interact with a range of exogenous and endogenous compounds. It is predominately present in the extracellular space, with high concentration being reported in the skin, guts, muscles, fluids (cerebrospinal, pleural), and secretions such as sweat, tear, milk, and saliva [10]. The well-known fact about albumin is that there is a complex relationship between the inflammation and albumin level in the extracellular matrix under various physiological and pathological conditions [11–13]. The earlier studies indicated that the stressed and inflamed cells increase the uptake of albumin [11–13].

We are suggesting the use of combinatorial drugs therapy, in which one drug inhibits the fusion and entry of the virus into the cells and another drug internalizes and targets multiple viral components inside the cell and/or cell signaling to halt the viral propagation (see Fig. 1).

Table 1 shows the list of drugs that have been shown to improve the state of the SARS-CoV-2 infected patients [8,14]. The drug combination has been chosen in such a way that it can effectively neutralize both extracellular and intracellular viral components. Furthermore, the serum albumin should be used to maximize the cellular internalization and enhance the pharmacological effects. A similar strategy based on the proposed concept was utilized in the influenza virus-infected mouse liver cells, where it yielded a positive outcome [15].

A recent search for the treatment of SARS-CoV-2 infection in PubMed revealed the usefulness of traditional medicine in treating the COVID-19 in the current pandemic [16]. For example, research indicated the high potential of the Epigallocatechin gallate (EGCG) and Curcumin in neutralizing the range of viruses [17–22]. The recent studies support the albumin therapy of COVID-19 patients since there is the complex relation of albumin concentration and ACE2 receptor expression in the cells, ACE2 receptors are crucial in mediating the virus infection [23]. If the albumin is used to stabilize and deliver the EGCG and Curcumin for targeting the intracellular virus components in combination with the drug that could block the virus fusion and/or entry to a cell, this strategy might represent an effective way of treating the SARS CoV-2 infection. EGCG and Curcumin combination is proven to be very effective in treating various pathological conditions by augmenting the key cellular signaling [24–26]. The inhibition of these key cellular pathways also helps in inhibiting the virus multiplication inside the cells as reported in the case of SARS-CoV [27–29]. In addition to their antiviral outcomes, curcumin and EGCG are known for their health-boosting properties [30,31].

Conclusion

In light of presented facts complemented by the referenced publications, it is highly recommended to use albumin as a therapeutic material, stabilizer, and deliverer of the drugs (such as known antiviral drugs and traditional molecules) that could effectively target the extracellular and intracellular viral components in the therapy of patients infected with SARS-CoV-2.

Competing interests

None declared.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

The authors acknowledge the funding support from the Council of Scientific and Industrial Research (CSIR), India. The file no. for the same is 09/1058(0013)/2019-EMR-I. The authors also acknowledge the host support and facilities provided by the Indian Institute of Technology Mandi, Himachal Pradesh, India.

Fig. 1. Schematic representation of effective strategies for the treatment of SARS-CoV-2 infection.
Table 1
List of the drug molecules currently in use for treating the patients infected with SARS-CoV-2.

| S. No. | Drug                          | Description/Mechanism of action                                                                 |
|-------|-------------------------------|-----------------------------------------------------------------------------------------------|
| 1     | Hydroxychloroquine            | Decrease TLR signaling thus reduce activation of dendritic cells and inflammatory processes   |
| 2     | Interferon alpha-1            | Induce the synthesis of key antiviral mediators and activate cytotoxic T cells                 |
| 3     | Lopinavir                     | Inhibit the activity of an enzyme critical for the HIV lifecycle                               |
| 4     | Remdesivir                    | Interfere with the activity of RNA polymerase thus could be effective in treating the variety of RN viruses. |
| 5     | Ribavir                       | Protease inhibitor activity against HIV-1                                                    |
| 6     | Sofosbuvir                    | Inhibit the Hepatitis C NS5B protein thus used in the treatment of Hepatitis C infection      |
| 7     | Umifenovir                    | Used in the prophylaxis and treatment of respiratory virus infection                          |
| 8     | Alfa-interferon               | Broad-spectrum of Antiviral and Immune-regulatory activity with the subtypes acting synergistically to give a wide range of response |
| 9     | Corticosteroids               | Class of steroid hormone use in the treatment of various physiological and pathological conditions |
| 10    | Ribavir                       | Interfere in the RNA metabolism, such as blocking the viral RNA synthesis and mRNA capping require for viral replication |

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.mehy.2020.109790.

References

[1] Wang H, Wang Z, Dong Y, Chang R, Xu C, Yu X, et al. Phase-adjusted estimation of the number of Coronavirus Disease 2019 cases in Wuhan, China. Cell Discov 2020;6:1-8. https://doi.org/10.1038/s41433-020-0148-0.

[2] Coronavirus (COVID-19) map n.d. https://google.com/covid19-map/?hl=en (accessed April 2, 2020).

[3] Genomic Study Points to Natural Origin of COVID-19 – NIH Director’s Blog n.d. https://directorsblog.nih.gov/2020/03/26/ (accessed April 2, 2020).

[4] Virus Pathogen Database and Analysis Resource (ViPR) – Severe acute respiratory syndrome coronavirus 2 isolate Wuhan-Hu-1, co- transmission: a study of a family cluster. Lancet 2020;395:514-521. https://doi.org/10.1016/S0140-6736(20)31544-9.

[5] Finicle BT, Jayashankar V, Edinger AL. Nutrient scavenging in cancer. Nat Rev Cancer 2018;18:619-630. https://doi.org/10.1038/s41568-018-0048-x.

[6] The potential use of albumin in COVID-19 patients | The BMJ n.d. https://www.bmj.com/content/368/bmj.m810/rr-41 (accessed April 8, 2020).

[7] Mathew D, Hsu WL. Antiviral potential of curcumin. J Funct Foods 2018;40:692-700. https://doi.org/10.1016/j.jff.2017.12.017.

[8] Chu C, Deng J, Man Y, Qu Y. Green tea extracts (-)-epigallocatechin-3-gallate inhibits colorectal carcinoma microenvironment-induced angiogenesis by JAK/STAT3/IL-8 pathway. Oncogenesis 2017;6:e384. https://doi.org/10.1038/oncsis.2017.84.

[9] Zhou DH, Wang X, Yang M, Shi X, Huang W, Feng Q. Combination of low concentration of (-)-epigallocatechin-gallate inhibits colorectal carcinoma microenvironment-induced angiogenesis by JAK/STAT3/IL-8 pathway. Oncogenesis 2017;6:e384. https://doi.org/10.1038/oncsis.2017.84.

[10] Zhou DH, Wang X, Yang M, Shi X, Huang W, Feng Q. Combination of low concentration of (-)-epigallocatechin-gallate inhibits colorectal carcinoma microenvironment-induced angiogenesis by JAK/STAT3/IL-8 pathway. Oncogenesis 2017;6:e384. https://doi.org/10.1038/oncsis.2017.84.

[11] Hewlings SJ, Kalman DS. Curcumin: A Review of Its Effects on Human Health n.d. https://doi.org/10.3390/foods6100992.

[12] Mani Mishra, et al. Antimicrob Agents Chemother 2020. https://doi.org/10.1128/AAC.00483-20.

[13] Mathew D, Hsu WL. Antiviral potential of curcumin. J Funct Foods 2018;40:692-700. https://doi.org/10.1016/j.jff.2017.12.017.

[14] Lai YH, Sun CP, Huang HC, Chen JC, Liu HK, Huang C. Epigallocatechin gallate inhibits hepatitis B virus infection in human liver chimeric mice. BMC Complement Altern Med 2018;18:248. https://doi.org/10.1186/s12906-018-2316-4.

[15] Li J, Song D, Wang S, Dai Y, Zhou J, Gu J. Antiviral effect of epigallocatechin gallate via impairing porcine circovirus type 2 attachment to host cell receptor. Virus Genes 2020;12. https://doi.org/10.1007/s11262-020-0177-5.

[16] DeDiego ML, Nieto-Torres JL, Regla-Nava JA, Jimenez-Guardano JM, Fernandez-Delgado R, Fett C, et al. Inhibition of NF-κB-mediated inflammation in severe acute respiratory syndrome coronavirus-infected mice increases survival. J Virol 2014;88:913-24. https://doi.org/10.1128/jvi.02576-13.

[17] Lai YH, Sun CP, Huang HC, Chen JC, Liu HK, Huang C. Epigallocatechin gallate inhibits hepatitis B virus infection in human liver chimeric mice. BMC Complement Altern Med 2018;18:248. https://doi.org/10.1186/s12906-018-2316-4.

[18] Mani Mishra, et al. Antimicrob Agents Chemother 2020. https://doi.org/10.1128/AAC.00483-20.